About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 438 record(s)
Req # A-2022-000065
Adverse Drug Reactions (ADRs) for Immunoglobulin (human). Report numbers: E2B_05023522, E2B_05075235, E2B_05078453, E2B_05008371, E2B_05043180, 000981354. ADRs for Agalsidase alfa. Report numbers: E2B_05049007, E2B_04983028. ADR for Lanadelumab. Report number: E2B_04978267.Organization: Health Canada
July 2022
Req # A-2022-000076
Adverse Drug Reaction (ADR) for METFORMIN HYDROCHLORIDE. Report number: E2B_05082566.Organization: Health Canada
July 2022
Req # A-2022-000080
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_02647003, E2B_02646771.Organization: Health Canada
July 2022
Req # A-2022-000083
Adverse Drug Reaction (ADR) for CROMOGLICATE SODIUM. Report number: 000980457. ADR for METRONIDAZOLE. Report number: E2B_04620910. ADR for ZOPICLONE. Report number: E2B_05053501.Organization: Health Canada
July 2022
Req # A-2022-000085
Adverse Drug Reactions (ADRs). Report numbers: E2B_04819838, E2B_04820998, E2B_04821007, E2B_04821009, E2B_04821032, E2B_04821033, E2B_04821576, E2B_04824693, E2B_04824893, E2B_04824896.Organization: Health Canada
July 2022
Req # A-2022-000094
Adverse Drug Reactions (ADRs) for Cancidas. Report numbers: 000732525, E2B_01439413, E2B_02476209, E2B_01460423, E2B_01446787, E2B_02218731, E2B_02129303, E2B_02595082, E2B_02780049, E2B_02223765.Organization: Health Canada
July 2022
Req # A-2022-000096
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB, FUROSEMIDE DANAZOL. Report numbers: E2B_04983075, E2B_05082215, E2B_05056270.Organization: Health Canada
July 2022
Req # A-2022-000100
Adverse Drug Reactions (ADRs) for CANCIDAS. Report numbers: E2B_00949425, E2B_01971678, E2B_01004598, 000715060, 000723631, E2B_02240616, E2B_02466827, E2B_00949425, E2B_02470337, E2B_02250176.Organization: Health Canada
July 2022
Req # A-2022-000101
Adverse Drug Reactions (ADRs) for CANCIDAS. Report numbers: E2B_02299849, AER000723632, E2B_02248414, AER000673581, E2B_00232128, E2B_00140861, E2B_00146625, AER000629121, E2B_01477765, E2B_02569986.Organization: Health Canada
July 2022
Req # A-2022-000115
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB, ALFUZOSIN HYDROCHLORIDE, ANTI-THYMOCYTE GLOBULIN (RABBIT). Report numbers: 000978791, E2B_05053755, E2B_04982469, E2B_04978800, E2B_05043181, E2B_05009478, E2B_05007203, E2B_05009481, E2B_04314360.Organization: Health Canada
July 2022